Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor α in epithelial ovarian cancer

European Journal of Gynaecological Oncology

Volumn 17, Issue 6, 1996, Pages 487-492

  Goff, B A ^a   Shy, K ^a   Greer, B E ^a   Muntz, H G ^a   Skelly, M ^a   Gown, A M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); HER 2 neu; Ki 67; Ovarian cancer; p53; Tumor necrosis factor (TNF )

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CANCER; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CULTURE TECHNIQUES; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029832861     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Slamon D. J., Godolphin W., Jones L. A., Holt J. A.,Wong S. G., Keith D. E. et al.: "Studies of the HER-2/neu protooncogene in human breast and ovarian cancer"'. Science, 1989, 244, 707.
2. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R. et al.: "Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer" Cancer Research, 1990, 50, 4087.
3. Patk S., Hazan R., Fisher E. R. et al.: "Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer". J. Clin. Oncol., 1990, 8, 103.
4. Hetzel D. J., Wilson T. O., Keeney G. L., Roche P. C., Cha S. S., Podratz K. C.: "HER-2/neu expression: a major prognostic factor in endometrial cancer". Gynecol. Oncol., 1992, 47, 179.
5. Berchuck A., Soisson A. P., Olt G. J., Soper J. T., Clarke-Pearson D. L., Bast R. C. Jr. et al.: "Epidermal growth factor expression in normal and malignant endometrium". Am. J. Obstet. Gynecol., 1989, 161, 1247.
6. Berchuck A., Rodnguez G. C., Kamel A., Dodge R. K., Soper J. T., Clarke-Pearson D. L., Bast R. C. Jr.: "Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer". Am. J. Obstet. Gynecol., 1991, 164, 669.
7. Grimaux M., Romain S., Remvikos Y., Martin P. M., Magdelenat H.: "Prognostic value of epidermal growth factor receptor in node-positive breast cancer". Breast Cancer Res. Treat., 1989, 14, 77.
8. Chang F., Syrjanen S., Syrjanen K.: "Implication of the p53 tumor-suppressor gene in clinical oncology". J. Clin. Oncol., 1995, 13, 1009.
9. Porter P. L., Gown A. M., Kramp S. G., Coltrera M. D.: "Widespread p53 overexpression in human malignant tumors". Am. J. Pathol., 1992, 140, 145.
10. Bosari S., Viale G., Radaelei V., Bossi P., Bonoldi E., Coggi G.: "p53 accumulation in ovarian carcinomas and its prognostic implications". Hum. Pathol., 1993, 24, 1175.
11. Berchuck A., Kohler M. F., Marks J. R., Wiseman R., Boyd J., Bast R. C. Jr.: "The p53 tumor suppressor gene frequently is altered in gynecologic cancers". Am. J. Obstet. Gynecol., 1994, 170, 246.
12. Toffoli G., Doglioni C., Cernigoi C., Frustaci S., Perin T., Canal B. et al: "p53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness". Ann. Oncol., 1994, 5, 167.
13. Beck T., Weller E. E., Weikel W, Brumm C., Wilkens C., Knapstein P. G.: "Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB1". Gynecol. Oncol., 1995, 57, 96.
14. Naylor M. S., Stamp G. W. H., Foulkes W. D., Eccles D., Balkwill F. R.: "Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression". J. Clin. Invest. 1993, 91, 2194.
15. Moradi M. M., Carson L. F., Weinberg J. B., Haney A. F., Twiggs L. B., Ramakrishnan S.: "Serum and ascitic fluid levels of interleukin-1. interleukin-6. and tumor necrosis factor-alpha in patients with ovarian epithelial cancer". Cancer, 1993, 72, 2433
16. Wu S., Rodabaugh K., Martinez-Maza O., Watson J. M., Silberstein D. S., Boyer C. M. et al.: "Stimulation of ovarian tumor cell proliferations with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor α". Am. J. Obstet. Gynecol., 1992, 166, 997.
17. Wu S., Boyer C. M., Whitaker R. S. et al.: "Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression". Cancer Research. 1993, 53, 1939.
18. Jordan P. A., Kerns B. M., Pence J. M., Kohler M. F., Bast R. C. Jr, Kinney R. B. et al.: "Determination of proliferation index in advanced ovarian cancer using quantitative image analysis". Am. J. Clin. Pathol., 1993, 99, 736.
19. Cattoretti G., Becker M. H. G., Keg G., Duchrow M., Schluter C., Galle J. et al.: "Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave processed formalin fixed paraffin sections". J. Pathol., 1992, 168, 357.
20. Kroese M. C., Rutgers D. H., Wils I. S., Van Unnik J. A., Roholl P. J., "The relevance of DNA index and proliferation in the grading of benign and malignant soft tissues". Cancer, 1990, 65, 1782.
21. Henriksen R., Strang P., Wilander E., Backstrom T., Tribukaite B., Oberg K.: "p53 expression in epithelial ovarian neoplasms: relationships to clinical and pathological parameters. Ki-67 expression and flow cytometry". Gynecol. Oncol., 1994, 53, 301.
22. Gown A. M., Vogel A. M.: "Monoclonal antibodies to human intermediate filament proteins". Am. J. Pathol., 1984, 114, 309.
23. Gown A. M., DeWever N., Battifora H.: "Microwave based antigenic unmasking: a revolutionary new technique for routine immunohistochemistry". App. Immimohistochem., 1993, 1, 256.
24. Hsu S. M., Soban E.: "Color modification of diaminoben-zidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry". J. Histochem. Cytochem., 1982, 30, 1079.
25. Garica R. L., Coltrera M. D., Gown A. M.: "Analysis of proliferative grade anti-PCNA/cyclin monoclonal antibodies in fixed, embedded sections: comparison with flow cytometric analysis". Am. J. Pathol., 1989, 134, 733.
26. Rubin S. C., Finstad C. L., Wong G. Y., Almadrones L., Plante M., Lloyd K. O.: "Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis". Am. J. Obstet. Gynecol., 1993, 168, 162.
27. Rubin S. C., Finstad C. L., Federici M. G., Scheiner L., Lloyd K. O., Hoskins W. J.: "Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer". Cancer, 1994, 73, 1456.
28. Hruza C., Dobianer K., Beck A., Czerwenka K., Hanak H., Klein M. et al.: "HER-2/neu and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples". Eur. J. Cancer, 1993, 29A, 1593.
29. Leary J A., Edwards B. G., Hougton C. R. S.: "Amplification of HER-2/neu oncoaene in human ovarian cancer". Int. J. Gynecol. Oncol., 1993, 2, 291.
30. Kerns B. M., Jordan P. A., Faerman L. L., Berchuck A., Bast R. C. Jr., Layfield L. J.: "Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis". Am. J. Clin. Pathol., 1994, 101, 192.
31. Scambia G., Panici P. B., Battaglia F., Ferrandina G., Baiocchi G., Greggi S. et al.: "Significance of epidermal growth factor in advanced ovarian cancer". J. Clin. Oncol., 1992, 10, 529.
32. van Dam P. A., Vergote I. B., Lowe D. G., Watson J. V., van Damme P., van der Auwera J. C. et al.: "Expression of c-erbB-2. c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I. and epidermal growth factor in ovarian carcinoma". J. Clin. Pathol., 1994, 47, 914.
33. van der Burg M. E., Henzen-Logmans S. C., Foekens J. A., Berns E. M. Rodenburg C. J., van Putten W. L. et al.: "The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study". Eur. J. Cancer, 1993, 29A, 1951.
34. Gotleib W. H., Berek J. S.: "Advances in the biology of gynecologic cancer". Current Opinion in Oncology, 1994, 6, 513.
35. Hartmann L. C., Podratz K. C., Keeney G. L., Kamel N. A., Edmonson J. H., Grill J. P. et al.: "Prognostic significance of p53 immunostaining in epithelial ovarian cancer". J. Clin. Oncol. 1994, 12, 64.
36. Marks J. R., Davidoff A. M. Kerns B. J., Humphrey P. A., Pence J. C., Dodge R. K. et al.: "Overexpression and mutation of p53 in epithelial ovarian cancer". Cancer Res., 1991, 51, 2979.
37. Jussila T., Stenback F.: "Cell proliferation markers and growth factors in ovarian cancer". Ann. Med., 1995, 27, 87.
38. Isola J., Kallioniemi O. P., Korte J. M., Wahlstrom T., Aine R., Helle H. et al.: "Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytoraetry, biochemical receptor assay, and patient survival". J. Pathol., 1990, 162, 295.